Hormonal
GLP-1 receptor agonists (Liraglutide 3.0 mg and Semaglutide 2.4 mg) produce superior weight loss and cardiovascular risk reduction compared to other pharmacotherapies, making them first-line pharmacological options for high-risk patients.
If lifestyle changes alone are insufficient, GLP-1 medications like Semaglutide or Liraglutide are the most effective pharmacological options, offering significant weight loss (up to 12+ kg) and cardiovascular benefits. They require weekly or daily injections and slow dose titration to manage side effects. Discuss cost and insurance coverage with your provider to determine if this is a viable long-term strategy.
Liraglutide (3.0 mg) and semaglutide (2.4 mg) have shown the strongest weight loss effects among currently approved anti-obesity drugs... These drugs should be considered as the first choice for obese patients with type 2 diabetes if conditions permit.
Why this rating
Based on multiple large-scale clinical trials (STEP, SURMOUNT, etc.) and meta-analyses cited in the guideline.
Source
Guidelines for obesity clinic consultations in primary healthcare clinics
Jee‐Hyun Kang et al. · Journal of Korean Medical Association · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →